Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With Dinutuximab Beta, Irinotecan, and Temozolomide for Refractory or Relapsed Neuroblastoma in Children
NCT07318831Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in neuroblastoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jan 2026; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07318831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318831.